CIBC World Markets Inc. Raises Position in Iqvia Holdings Inc (IQV)

CIBC World Markets Inc. boosted its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 202.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,323 shares of the medical research company’s stock after buying an additional 8,253 shares during the quarter. CIBC World Markets Inc.’s holdings in Iqvia were worth $1,209,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Private Capital Group LLC grew its holdings in Iqvia by 177.0% in the first quarter. Private Capital Group LLC now owns 1,061 shares of the medical research company’s stock worth $104,000 after purchasing an additional 678 shares during the last quarter. Point72 Asia Hong Kong Ltd purchased a new position in Iqvia in the first quarter worth $124,000. Focused Wealth Management Inc purchased a new position in Iqvia in the fourth quarter worth $166,000. TLP Group LLC grew its holdings in Iqvia by 1,476.7% in the first quarter. TLP Group LLC now owns 2,034 shares of the medical research company’s stock worth $200,000 after purchasing an additional 1,905 shares during the last quarter. Finally, Kendall Capital Management purchased a new position in Iqvia in the fourth quarter worth $224,000. 89.83% of the stock is currently owned by institutional investors.

Several research firms have issued reports on IQV. ValuEngine raised shares of Iqvia from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised shares of Iqvia from a “strong sell” rating to a “hold” rating in a report on Friday, March 23rd. Goldman Sachs Group raised shares of Iqvia from a “neutral” rating to a “buy” rating in a report on Friday, April 13th. Robert W. Baird raised shares of Iqvia from a “neutral” rating to an “outperform” rating in a report on Monday, June 18th. Finally, Argus boosted their price objective on shares of Iqvia from $110.00 to $112.00 and gave the company a “buy” rating in a report on Monday, April 9th. Seven equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Iqvia currently has an average rating of “Buy” and a consensus target price of $110.47.

In other Iqvia news, major shareholder Cpp Investment Board Private H sold 9,291,036 shares of the company’s stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $103.00, for a total value of $956,976,708.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael J. Evanisko sold 815 shares of the company’s stock in a transaction dated Wednesday, April 18th. The stock was sold at an average price of $100.00, for a total transaction of $81,500.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,825,247 shares of company stock valued at $1,115,016,428. Insiders own 6.00% of the company’s stock.

NYSE IQV opened at $99.82 on Friday. The firm has a market cap of $20.36 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 1.65 and a beta of 0.64. Iqvia Holdings Inc has a 1 year low of $87.45 and a 1 year high of $110.67. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.16 and a quick ratio of 1.16.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Wednesday, May 2nd. The medical research company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.07. The business had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.42 billion. Iqvia had a net margin of 13.07% and a return on equity of 13.35%. The company’s revenue for the quarter was up 34.1% on a year-over-year basis. equities analysts predict that Iqvia Holdings Inc will post 5.07 EPS for the current fiscal year.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply